200
Participants
Start Date
August 18, 2023
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
Peking University Third Hospital /ID# 257722, Beijing
The First Hospital of China Medical University /ID# 257641, Shenyang
Huashan Hospital, Fudan University /ID# 256456, Shanghai
Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 257726, Shanghai
Shanghai Skin Disease Hospital /ID# 257719, Shanghai
Shandong Dermatological Hospital /ID# 257727, Jinan
Hangzhou First People's Hospital /ID# 261867, Hangzhou
The second affiliated hospital of Zhejiang University school of medicine /ID# 257723, Hangzhou
Ningbo First Hospital /ID# 263884, Ningbo
The First Affiliated Hospital Of Fujian Medical University /ID# 257725, Fuzhou
Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 257724, Wuhan
People's Hospital of Henan Province /ID# 257736, Zhengzhou
Dermatology Hospital of Southern Medical University /ID# 261862, Guangzhou
The Eighth Affiliated Hospital, Sun Yat-sen universtiy /ID# 257737, Shenzhen
Chengdu Second Municipal People's Hospital /ID# 257732, Chengdu
West China Hospital, Sichuan University /ID# 257720, Chengdu
Sichuan Provincial People's Hospital /ID# 263898, Chengdu
Second Affiliated Hospital of Xian Jiaotong University /ID# 257733, Xi'an
Lead Sponsor
AbbVie
INDUSTRY